closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PATIENTS WITH ENTHESITIS ACHIEVED RESOLUTION1*

Sustained resolution of preexisting enthesitis up to 3 years1,a

aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.

Patients treated with OTEZLA 30 mg BID achieved
significantly greater improvement vs placebo in MASES (enthesitis)
score (mean change of -1.3 vs 0.9, P = 0.0194) at week 241†

*Pooled patient data from PALACE 1-3; includes all randomized patients with preexisting enthesopathy (baseline MASES score >0; n = 945). Resolution was defined as a MASES score of 0.

LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.

BID, twice daily; LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.

PATIENTS WITH ENTHESITIS ACHIEVED RESOLUTION IN A REAL-WORLD SETTING2*

Resolution of preexisting enthesitis at months 1 and 42,a

aLAPIS-PsA study, interim analysis at 4 months. Data as observed among patients with value available at specified time point.

In a real-world setting, OTEZLA led to complete resolution of enthesitis2†

*Among patients with an LEI >0 at baseline (n = 49/111, 44.5%).

Defined as LEI = 0.

LAPIS-PsA, Study of Apremilast Use in Patients with Psoriatic Arthritic in Practice Conditions; LEI, Leeds Enthesitis Index.

Reference:

  1. Gladman DD, et al. Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase III clinical development program. Ann Rheum Dis. 2017;76 (suppl 2): Abstract SAT0448.
  2. Wollenhaupt J, Vollmer M, Berger S, et al. Real-world insights on apremilast treatment in psoriatic arthritis patients: interim analysis of the multicenter LAPIS-PsA study. Presented at: the 45th Congress of the German Society of Rheumatology (DGRh); 6-9 September 2017; Stuttgart, Germany.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil